Background: Legume allergy, mainly to lentils and chickpeas, is the fifth most common cause of food allergy in Spanish children. Serological cross-reactivity among legumes is frequent, but its clinical relevance is controversial. The aim of this study was to investigate the cross-reactivity among lentils, chickpeas, peas, white beans and peanuts and its clinical relevance in pediatric patients. Methods: Fifty-four children with clinical allergy to legumes were included. Cross-reactivity was evaluated by ELISA inhibition experiments and oral food challenges to legumes. SDS-PAGE immunoblots were conducted with raw and boiled legume extracts. Results: ELISA inhibition experiments demonstrated more than 80% inhibition with lentil, chickpea and pea extracts. Immunoblots performed with raw legume extracts (lentil, chickpea and pea) and individual sera revealed that more than 50% of the sera identified an allergen with approximately 50 kDa in all three legume extracts. In all three boiled extracts an intense band at approximately 50 kDa was visualized using a serum pool. The oral legume challenges demonstrated that 37 children (69%) were allergic to 2 or more legumes (median 3 legumes). The most frequent associations were allergy to lentils and chickpeas (57%), allergy to lentils and peas (54%) and allergy to lentils, chickpeas and peas (43%). Conclusions: In vitro inhibition experiments demonstrated a high degree of cross-reactivity among lentils, chickpeas and peas. Food challenges confirmed that clinical allergy to all three legumes is frequent in our cohort of Spanish children.

Keywords:
Legume allergy, Legume cross-reactivity, Legume allergens
1.
Young E, Stoneham MD, Petruckevitch A, Barton J, Rona R: A population study of food intolerance. Lancet 1994;343:1127–1129.
2.
Niestijil JJ, Kardinaal AF, Huijbers G, Vlieg-Boerstra BJ, Martens BP, Ockhuizen T: Prevalence of food allergy and intolerance in adult Dutch population. J Allergy Clin Immunol 1994;93:446–456.
3.
Sampson HA: Clinical practice. Peanut allergy. N Engl J Med 2002;346:1294–1299.
4.
Sampson HA: Adverse reactions to foods; in Allergy Principles and Practice, ed 5. Mosby Year Book, St. Louis, 1998.
5.
Crespo JF, Pascual C, Burks AW, Helm RM, Esteban MM: Frequency of food allergy in a pediatric population from Spain. Pediatr Allergy Immunol 1995;6:39–43.
6.
Bernhisel-Broadbent J, Taylor S, Sampson HA: Cross-allergenicity in the legume botanical family in children with food hypersensitivity. II. Laboratory correlates. J Allergy Clin Immunol 1989;84:701–709.
7.
Barnett D, Bonham B, Howden ME: Allergenic cross-reactions among legume food. An in vitro study. J Allergy Clin Immunol 1987;79:433–438.
8.
Bernhisel-Broadbent J, Sampson HA: Cross-allergenicity in the legume botanical family in children with food hypersensitivity. J Allergy Clin Immunol 1989;83:435–440.
9.
Ibáñez MD, Martínez M, Sánchez JJ, Fernández-Caldas E: Legume: cross-reactivity. Allergol Immunopathol 2003;31:151–161.
10.
Martín JA, Compaired JA, de la Hoz B, et al: Bronchial asthma induced by chick pea and lentil. Allergy 1992;47:185–187.
11.
Patil SP, Niphadkar PV, Bapat MM: Chickpea: a major food allergen in the Indian subcontinent and its clinical and immunochemical correlation. Ann Allergy Asthma Immunol 2001;87:140–145.
12.
López-Torrejon G, Salcedo G, Martin-Esteban M, Diaz-Perales A, Pascual CY, Sanchez-Monge R: Len c 1, a major allergen and vicilin from lentil seeds: protein isolation and cDNA cloning. J Allergy Clin Immunol 2003;112:1208–1215.
13.
Sanchez-Monge R, Lopez-Torrejon G, Pascual CY, Valera J, Martin-Esteban M, Salcedo G: Vicilin and convicilin are potential major allergens from pea. Clin Exp Allergy 2004;34:1747–1753.
14.
Boluda L, Casanovas M, Prieto JL, Fernandez-Caldas E: Determinations of Par j1 by a competitive enzyme immunoassay using human specific IgE and IgG. Validation by skin prick testing. J Invest Allergy Clin Immunol 1998;8:207–213.
15.
Martínez M, Ibáñez MD, Fernández-Caldas E, Marañón F, Muñoz MC, Laso MT: The diagnostic value of crude and boiled extracts to identify tolerant versus nontolerant lentil sensitive children. Ann Allergy Asthma Immunol 2001;86:686–690.
16.
Ibáñez Sandín MD, Martínez San Ireneo M, Marañón Lizana F, Fernández-Caldas E, Alonso Lebrero E, Laso Borrego T: Specific IgE determinations to crude and boiled lentil (Lens culinaris) extracts in lentil-sensitive children and controls. Allergy 1999;54:1209–1214.
17.
Martínez San Ireneo M, Ibáñez Sandín MD, Fernández-Caldas E, Marañón Lizana F, Rosales Fletes MJ, Laso Borrego MT: Specific IgE levels to Cicer arietinum (chick pea) in tolerant and nontolerant children: evaluation of boiled and raw extracts. Int Arch Allergy Immunol 2000;121:137–143.
18.
Wensing M, Knulst AC, Piersma S, O’Kane F, Knol EF, Koppelman SJ: Patients with anaphylaxis to pea can have peanut allergy caused by cross-reactive IgE to vicilin (Ara h 1). J Allergy Clin Immunol 2003;111:420–424.
19.
Moneret-Vautrin DA, Guerin L, Kanny G, Flabbee J, Fremont S, Morisset M: Cross-allergenicity of peanut and lupine: the risk of lupine allergy in patients allergic to peanuts. J Allergy Clin Immunol 1999;104:883–888.
20.
Peeters KA, Nordlee JA, Penninks AH, et al: Lupine allergy: not simply cross-reactivity with peanut or soy. J Allergy Clin Immunol 2007;120:647–653.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.